Abstract: The disclosure relates to a slow-release biodegradable composite pesticide plug that can be used for trunk injection delivery of pesticides to protect woody plants such as trees (e.g., fruit trees) against pests. The composite pesticide plug generally includes a thermoplastic polymer matrix with a water-soluble thermoplastic polymer component, a cellulosic reinforcement, and a pesticide or other active ingredient. After injection into the tree trunk, the composite pesticide plug provides a uniform, relatively consistent dose of pesticide or other active ingredient to all parts of the tree throughout the growing season, thus reducing waste of material and cost. The biodegradable nature of the composite plug also enhances the healing of the tree after injection.

Abstract: Provided herein are compositions and methods for wound healing. In particular, provided herein are spray dried suramin for use in wound healing and other applications.

Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.

Abstract: The present disclosure relates to a gel formulation for treating diabetic foot ulcer infections. The gel formulation comprises antibiotic loaded aquasomes, a gelling agent, a preservative, and a fluid medium. The gel formulation of the present disclosure can be used for treating diabetic foot ulcer infections in mammals.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Disclosed herein is an analgesic solution for the treatment of pain comprising a pain-relieving effective amount of tramadol or a pharmaceutically acceptable salt thereof, a method of treating pain by administering said analgesic solution to a subject in need thereof, a kit that includes containers of the analgesic solution, and a dosing regimen for the analgesic solution.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: The present invention provides granular compositions containing soil-applied pesticides. In particular, the present invention provides granular compositions containing insecticides, especially soil-applied insecticides, and more specifically still, certain pyrethroid insecticides, such as tefluthrin. The present invention provides also the use of the granular compositions for controlling insects, and methods of controlling insects by application of the granular compositions.

Abstract: The invention relates to an oil-in-water emulsion for making up or caring for the lips. This emulsion contains a high proportion of glossy oils and is very fluid while remaining stable. This emulsion contains from 35% to 60% by weight of a mixture of oils, at least 25% by weight of water and from 0.01% to 20% of coloring material, everything being stabilized by the combination of a first polyethylene glycol ether of stearyl alcohol comprising from 2 to 5 oxyethylene units, a second polyethylene glycol ether of stearyl alcohol comprising from 15 to 25 oxyethylene units, and of a copolymer of acrylamido-2-methylpropane sulfonate and of hydroxyethyl acrylate.

Abstract: A composition in which the volatile silicone is partially or fully replaced by a plant oil. The plant oil containing composition is parity or better than the volatile silicone containing material but at lower cost. One example comprises a mixing product of at least one material chosen from antiperspirant actives and deodorant actives; greater than 10 weight % of a plant oil: and less than 40 weight % of a volatile silicone oil. Another examples comprises a mixing product of greater than 10 weight % of a plant oil; a gellant for the composition; and less than 40 weight % of a volatile silicone oil, wherein the composition does not contain an antiperspirant active or deodorant active.

Abstract: A multi-step method of making a mammalian subcutaneous medical implant or non-implant for releasing self-contained drugs on a controlled basis over at least a 3 day period includes depositing at least portions of one or more individual layers of the implant by at least one computer controlled 3-D printer. The 3-D printing method may be accomplished via an array of 3-D nozzles that deposit materials (such as plastics, thermoplastics, coating materials, drug-containing matrix materials, non-drug containing matrix materials, bonding materials, biodegradable materials and/or the like) in very small, precise portions. The materials may be deposited in liquid, powder, sheet or other forms. Non-implant forms may also be provided by the techniques disclosed herein.

Abstract: A treatment agent for a cosmetic powder is provided. The treatment agent contains a reactive organosiloxane represented by the following general formula (1) as a main ingredient: In general formula (1): each R1 is independently an alkyl group having 1 to 30 carbon atoms; each R2 is independently an alkyl group having 1 to 20 carbon atoms; R3 is a divalent alkylene group; n is an integer of 1 to 200; and p is an integer of 1 to 3. The treatment agent for a cosmetic powder of this disclosure is capable of imparting excellent lipophilicity. A cosmetic raw material having cosmetic effect and giving an excellent feeling of use, and a cosmetic are also provided.

Abstract: A subject of the present invention is to provide a cosmetic for unevenness correction which has an excellent effect of concealing wrinkles and pores and correcting skin unevenness and has good compatibility with a makeup cosmetic. The present inventors have found that the cosmetic for unevenness correction which conceals wrinkles and pores and has good compatibility with a makeup cosmetic at the time of application can be easily provided by using a polyacrylate water-absorbing polymer having a specific water absorption capacity, but not a water-soluble macromolecule having a thickening effect commonly used in cosmetics, and they thus have completed the present invention.

Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: The present invention provides a liquid dispersion capable of stably maintaining the dispersed state for a long time and suitably applicable to both O/W type cosmetic products and W/O type cosmetic products. The present invention also provides a cosmetic raw material containing the liquid dispersion and a cosmetic product containing the liquid dispersion. The present invention provides a liquid dispersion containing a polyol (A); a nonionic surfactant (B); and a hydrophobized inorganic powder (C), wherein the water content in 100% by mass of the liquid dispersion is 1% by mass or less.

Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.

Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Abstract: Method of treating trichomoniasis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) at least 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; or (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; or (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.

Abstract: Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) at least 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; or (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; or (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.